2006
Living donor liver transplantation for hepatitis C‐related cirrhosis: No difference in histological recurrence when compared to deceased donor liver transplantation recipients
Guo L, Orrego M, Rodriguez‐Luna H, Balan V, Byrne T, Chopra K, Douglas DD, Harrison E, Moss A, Reddy KS, Williams JW, Rakela J, Mulligan D, Vargas HE. Living donor liver transplantation for hepatitis C‐related cirrhosis: No difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transplantation 2006, 12: 560-565. PMID: 16555313, DOI: 10.1002/lt.20660.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationDonor liver transplantationLiver transplantationHistological recurrenceHepatitis CDeceased-donor liver transplantation (DDLT) recipientsEnd-stage liver disease (MELD) scoreDonor liver transplantation recipientsHepatitis C virus infectionKaplan-Meier survival analysisDetectable HCV RNAHistological recurrence rateC virus infectionGraft survival ratesLiver Disease scoreActivity of inflammationLiver transplantation recipientsStatistical differenceChild-TurcotteDDLT groupLDLT patientsPugh scoreRecurrent HCVLiver transplantYears posttransplantation
2004
Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1
Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1. Transplantation 2004, 77: 190-194. PMID: 14742979, DOI: 10.1097/01.tp.0000100481.14514.bb.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsDrug Therapy, CombinationFemaleHepacivirusHepatitis CHumansImmunosuppressive AgentsInterferon alpha-2Interferon-alphaLiver Function TestsLiver TransplantationMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRecurrenceReverse Transcriptase Polymerase Chain ReactionRibavirinRNA, ViralTime FactorsTreatment OutcomeConceptsOrthotopic liver transplantationEnd of treatmentHCV recurrenceLiver transplantationPEG-IFNHepatitis C virus recurrenceRecurrent hepatitis C infectionDiscontinuation of therapyNecro-inflammatory scoreUndetectable viral loadHepatitis C infectionResponse 6 monthsBone marrow toxicityReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionHistologic benefitRecurrent HCVVirologic clearanceC infectionVirologic responseVirus recurrenceAggressive managementCombination regimenViral clearanceViral response